New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants

Abstract

A high percentage of preterm infants fails to respond to a single course of indomethacin or ibuprofen. Thus, it has been suggested that the actual dose regimens of these drugs could be inadequate because of large interindividual pharmacokinetics variations in premature infants. We tested the hypothesis that a high-dose regimen of ibuprofen was more effective than the current regimen in closing PDA. We demonstrated that a single course of ibuprofen at 20-10-10 mg/kg/day is more effective than a 10-5-5 mg/kg/day course in closing PDA without significant adverse effects. Many other questions regarding the pharmacological treatment of PDA are still debated.